4.7 Article

Myeloma as a model for the process of metastasis: implications for therapy

期刊

BLOOD
卷 120, 期 1, 页码 20-30

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-01-379024

关键词

-

资金

  1. National Institutes of Health [R01CA133799, R01CA125690, R01CA154648]
  2. Millennium
  3. Bristol-Myers Squibb
  4. Noxxon
  5. Novartis
  6. Onyx
  7. Genzyme

向作者/读者索取更多资源

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of multiple myelomatous omas throughout the skeleton, indicating that there is continuous trafficking of tumor cells to multiple areas in the bone marrow niches. MM may therefore represent one of the best models to study cell trafficking or cell metastasis. The process of cell metastasis is described as a multistep process, the invasion-metastasis cascade. This involves cell invasion, intravasation into nearby blood vessels, passage into the circulation, followed by homing into predetermined distant tissues, the formation of new foci of micrometastases, and finally the growth of micrometastasis into macroscopic tumors. This review discusses the significant advances that have been discovered in the complex process of invasion-metastasis in epithelial carcinomas and cell trafficking in hematopoietic stem cells and how this process relates to progression in MM. This progression is mediated by clonal intrinsic factors that mediate tumor invasiveness as well as factors present in the tumor microenvironment that are permissive to oncogenic proliferation. Therapeutic agents that target the different steps of cell dissemination and progression are discussed. Despite the significant advances in the treatment of MM, better therapeutic agents that target this metastatic cascade are urgently needed. (Blood. 2012;120(1):20-30)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据